Medscape looks at whether kidney function estimates stay reliable once a patient has lost significant weight on a GLP-1 drug.
Recap by typeshit. Full story at Medscape.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
The Wall Street Journal reports black-market producers are pitching Americans substances for tanning, tissue repair and weight loss.
The FDA has added a new label warning to weight loss drugs such as Wegovy. Tap through for what the warning covers.
Loading…